Literature DB >> 2650951

Surgical management of advanced hemophilic arthropathy. An overview of 20 years' experience.

J V Luck1, C K Kasper.   

Abstract

Advanced hemophilic arthropathy often causes moderate to severe pain and significant incapacity by the third or fourth decade of life. Most of these patients can be managed conservatively with clotting factor replacement on demand, therapeutic exercises, antiinflammatory drugs, orthoses, and activity restriction. Some patients, however, have such severe pain and disability and frequent need for clotting factor replacement that reconstructive surgery is required. Over the last 20 years at the present authors' institution, 168 such procedures have been performed. Of these, 141 were primary procedures and 27 were reoperations for persisting or recurring symptoms, failed prostheses, and infection. End-result analysis at the latest follow-up examination indicates that all patients are improved in terms of recurrent hemarthroses and pain, and all but two are improved in terms of function. Results are analyzed and compared with existing reports in the world literature in order to determine appropriate indications for surgery and which procedures are most successful.

Entities:  

Mesh:

Year:  1989        PMID: 2650951

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  13 in total

1.  "la synoviorthèse" can more than synovitis!

Authors:  Jamshid Farahati
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03       Impact factor: 9.236

2.  Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.

Authors:  Marcus E Carr; Thomas P Loughran; John A Cardea; Wade K Smith; Jan G Kuhn; Maribeth V Dottore
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  Total Hip Arthroplasty in Hemophilia Patients: A Mid-term to Long-term Follow-up.

Authors:  Guo-Liang Wu; Ji-Liang Zhai; Bin Feng; Yan-Yan Bian; Chi Xu; Xi-Sheng Weng
Journal:  Orthop Surg       Date:  2017-11       Impact factor: 2.071

4.  Total hip replacement in patients with severe bleeding disorders. A 30 years single center experience.

Authors:  B Habermann; C Eberhardt; L Hovy; L Zichner; I Scharrer; A A Kurth
Journal:  Int Orthop       Date:  2006-05-20       Impact factor: 3.075

5.  Bilateral synchronous total hip arthroplasty for end-stage arthropathy in hemophilia A patients: A retrospective study.

Authors:  Bang Jian He; Qiang Mao; Ju Li; Shuai Jie Lv; Peijian Tong; Hong Ting Jin
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

6.  Functional outcomes following ankle arthrodesis in males with haemophilia: analyses using the CDC's Universal Data Collection surveillance project.

Authors:  H Lane; A-E-A Siddiqi; R Ingram-Rich; P Tobase; R Scott Ward
Journal:  Haemophilia       Date:  2014-03-16       Impact factor: 4.287

7.  Total knee arthroplasty in hemophiliacs: gains in range of motion realized beyond twelve months postoperatively.

Authors:  Atul F Kamath; John G Horneff; Angela Forsyth; Valdet Nikci; Charles L Nelson
Journal:  Clin Orthop Surg       Date:  2012-05-17

8.  Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.

Authors:  E Santagostino; S R Lentz; M Misgav; B Brand; P Chowdary; A Savic; Y Kilinc; Y Amit; A Amendola; L P Solimeno; T Saugstrup; I Matytsina
Journal:  Haemophilia       Date:  2014-10-02       Impact factor: 4.287

9.  The use of 185 MBq and 740 MBq of 153-samarium hydroxyapatite for knee synovectomy in haemophilia.

Authors:  J U M Calegaro; J Machado; R G Furtado; J S C de Almeida; A V P de Vasconcelos; M F de Barboza; A P de Paula
Journal:  Haemophilia       Date:  2013-12-16       Impact factor: 4.287

10.  Hip Arthropathy in Haemophilia.

Authors:  Christian Carulli; Anna Rosa Rizzo; Massimo Innocenti
Journal:  J Clin Med       Date:  2017-04-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.